Rob has worked in the area of securities law, corporate finance, venture capital and mergers & acquisitions since 1998. Prior to joining THP, he worked in Citigroup Global Markets’ San Francisco office focused on healthcare investment banking and acquisition finance.  Previously, Rob worked at the Securities & Exchange Commission in Los Angeles and the New York-based law firm of Cravath, Swaine & Moore.  Rob also served as a Peace Corps Volunteer in the Dominican Republic. Rob has represented THP on the boards of EditCo, Frontier Psychiatry, GrayHawk Health, InvisALERT, MedPricer (acquired by Premier), Nimble Therapeutics, Nivagen, Promptly, TrakCel, and Verogen and he has been a board observer at Akoya Biosciences (NASDAQ:AKYA), Freedom Innovations (acquired by Health Evolution Partners) and Specific Diagnostics (acquired by bioMérieux).  Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.